Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 38,444

Document Document Title
WO/2019/089676A8
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceu...  
WO/2020/099398A1
A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their u...  
WO/2020/102576A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/102575A1
The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates and salts of the solvates thereof, pharmaceutical compositions containing compounds of formula (I), as well as the use of compounds ...  
WO/2020/102096A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/099645A1
The present invention relates to new compounds that act as inhibitors of metallo-betalactamases (MBL). The present invention also relates to pharmaceutical compositions comprising such MBL inhibitors, and uses thereof in the treatment of...  
WO/2020/101382A1
The present invention provides a novel compound having a protein kinase inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof. The compound according to the present invention, stereoisomers thereof or ph...  
WO/2020/098635A1
Monobactam compounds and a use therefor. Specifically provided are chemical compounds represented by formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs thereof, preparation methods therefor, pharma...  
WO/2020/102098A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/099407A1
The present invention relates to herbicidally active thiadiazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising suc...  
WO/2020/099404A1
The present invention relates to herbicidally active thiadiazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising suc...  
WO/2020/102574A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/099367A1
Use of the compounds of the formula (I) wherein the substituents are as defined herein as herbicides. Compounds of formula (I) are also claimed.  
WO/2020/102150A1
This application relates to compounds of the following Formula: or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovasc...  
WO/2020/102100A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/097266A1
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...  
WO/2020/097258A1
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...  
WO/2020/095316A1
Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physi...  
WO/2020/095215A1
A compound of formula (I), wherein Ar1, R21, R23, R24, R25, R26, R27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the ...  
WO/2020/096416A1
The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically ac...  
WO/2020/094542A1
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...  
WO/2020/094524A1
The present invention relates to compounds of Formula (I) or an agronomically acceptable salt of said compounds wherein Q, R1, R2, n and m are as defined herein. The invention further relates to herbicidal compositions which comprise a c...  
WO/2020/095912A1
Provided is a novel compound that has a 5-HT5A receptor modulating action. The present invention is a compound that is represented by general formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 to R7, A, and L ...  
WO/2020/092401A1
The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...  
WO/2020/092404A1
The present invention is directed to a method of treating a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including hematologic malignancies that are refractive to chemotherapeutic and/or ...  
WO/2020/092196A1
Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to...  
WO/2020/092667A1
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression...  
WO/2020/089262A1
The present invention provides novel compounds which activate the Kv3 potassium channels. The compounds have the structure (Formula I), Separate aspects of the invention are directed to pharmaceutical compositions comprising said compoun...  
WO/2020/092375A1
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...  
WO/2020/084005A1
The present invention relates to compounds binding to calreticulin which selectively inhibit growth of CALR mutant cells and/or exhibit selective cytotoxicity towards CALR mutant cells, to pharmaceutical compositions comprising such comp...  
WO/2020/086728A1
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.  
WO/2020/085845A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure may be comprised in a light-emitting...  
WO/2020/083926A1
The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase in...  
WO/2020/083733A1
The present invention relates to the compounds of formula (I), and the N-oxides, stereoiso- mers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variablesare defined according to the description, (I) Th...  
WO/2020/086556A1
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed. (I)  
WO/2020/086533A1
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.  
WO/2020/083957A1
The present invention relates to novel antagonists of the A2B adenosine receptor and pharmaceutical compositions comprising said antagonists as well as their uses for the treatment and prevention of disorders known to be susceptible to i...  
WO/2020/082656A1
The prevent invention provides a macromolecule Thermally Activated Delayed Fluorescence (TADF) material, and further provides a TADF monomolecular white light material, which is synthesized from raw materials of first groups and second g...  
WO/2020/085493A1
An indazole compound represented by general formula (I) or a salt thereof [in the formula, X, R1, R2, ring A, L1, L2, L3, and R5 are as described in the specification].  
WO/2020/084300A1
The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical co...  
WO/2020/081282A1
The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating pati...  
WO/2020/078350A1
Disclosed is to a thiadiazole derivative and the uses thereof in preparing a drug for treating GLS1-associated diseases. Specifically disclosed is a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable ...  
WO/2020/079106A1
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, and m are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2020/080534A1
The present invention provides a method for controlling a plant disease by treating a plant or soil with a compound which has an excellent controlling effect on a plant disease and is represented by formula (I) [in the formula, Z represe...  
WO/2020/081450A1
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions...  
WO/2020/077437A1
II and III Provided herein are Topoisomerase II inhibitory compounds having the structure of Formulas II and III and compositions thereof for use in the treatment of cancer. In particular, the Topoisomerase II inhibitory compounds descri...  
WO/2020/073945A1
Disclosed are a bicyclic derivative inhibitor, a preparation method therefor, and application thereof. In particular, disclosed are a compound represented by general formula (I), a preparation method for same, a pharmaceutical compositio...  
WO/2020/076239A1
The present disclosure relates to a pharmaceutically acceptable salt of compounds (I), i.e. varlitinib, a method of producing the salt, a purer form of the free base obtainable from the salt, and a pharmaceutical composition comprising a...  
WO/2020/074403A1
The present invention relates to small molecule compounds capable of modulating appetite in a vertebrate animal, particularly in a mammal. The invention further relates to the use of the compounds of the invention in methods of treatment...  
WO/2020/075706A1
Provided is a novel compound that controls plant disease. This pyridone compound is a novel compound that is capable of controlling plant disease.  

Matches 1 - 50 out of 38,444